4//SEC Filing
Inrig Jula 4
Accession 0001415889-25-003819
CIK 0001438533other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 9:22 PM ET
Size
9.8 KB
Accession
0001415889-25-003819
Insider Transaction Report
Form 4
Inrig Jula
CHIEF MEDICAL OFFICER
Transactions
- Sale
Common Stock
2025-02-12$23.53/sh−2,568$60,426→ 89,602 total - Exercise/Conversion
Performance-based restricted stock units
2025-02-10−8,000→ 0 total→ Common Stock (8,000 underlying) - Exercise/Conversion
Common Stock
2025-02-10+8,000→ 92,170 total
Footnotes (3)
- [F1]On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.
- [F2]Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
- [F3]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001902368
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 9:22 PM ET
- Size
- 9.8 KB